LUPUS ANTICOAGULANT
Andy Nguyen,M.D./ UT-Medical School at Houston, Pathology/
Last Revision on: 12/9/96
- Biochemical aspects:
- Lupus anticoagulants have been identified as immunoglobulins
of the IgG or IgM class.
- Lupus inhibitors may interfere with
the phospholipid component of the complex involving in the
conversion of prothrombin to thrombin. In addition, they react
with cardiolipin, the phospholipid antigen used in serologic
tests for syphilis.
- Pathological Basis:
- Approximately 10% of patients with systemic lupus erythematosus
may have lupus anticoagulant.
- In the absence of any other predisposition to hemorrhage, such
patients do not bleed spontaneously. Indeed, it appears that
they are at an increased risk for thrombotic complications.
- Treatment:
- Treatment is not indicated.
- Monitor patients for thrombotic complications.
Diagnostic Criteria:
- APTT:abnormal
- Plt_neutralization_test:abnormal
- Tissue_thromboplastin_inhibition,1:100:abnormal
- Negative_bleeding_history
- Thrombosis_as_the_main_clinical_sign
- Mixing_APTT:not_corrected